health news arrowHome >> *Mental Illness >> FDA Okays Patch as Alternative ADHD Treatment Wed, 09 Jul 2008 GMT 
health news
  NEWS YOU CAN TRUST

Search Health News 
Browser Preferences
 Add to Favorites

Main Menu
 Home
 - - - - - Hot Topics - - - - -
 Bird Flu
 Drug Safety
 Stem Cell Research
 - - - - - - - - - - - - - - - - -
 Alternative Medicine
 Children's Health
 Diet & Nutrition
 Disabilities
 *Diseases & Conditions
 Drugs & Herbs
 Environmental Health
 Fitness & Exercise
 Genetic Research
 Health Insurance
 Medical Ethics
 Men's Health
 *Mental Illness
 Addictions & Dependencies
 Bipolar Disor
 Depression
 Schizophrenia
 Pain
 Parenting
 Public Health & Safety
 Senior Care
 *Sexual Health
 Women's Health
 World Health
 - - - - - - - - - - - - - - - -
 Web Links
 Contact Us: info@dailynewscentral.com

XML News Feeds


 

HEALTH NEWS

FDA Okays Patch as Alternative ADHD Treatment

PDF  Print  E-mail
 07 April, 2006  20:56 GMT

ADHD patch
Approval of the patch comes as use of methylphenidate and other ADHD drugs increases in the United States. Nearly 3.3 million Americans age 19 and younger used an ADHD drug last year, according to Medco Health Solutions Inc., a prescription drug benefit program manager.
The federal Food and Drug Administration approved on Thursday the first skin patch to treat attention deficit hyperactivity disorder in children. The patch, called Daytrana, designed to be worn for 9 hours, contains methylphenidate, which has been shown to help children with ADHD.

It is the same stimulant that is in Ritalin. The patch is made by Noven Pharmaceuticals Inc. of Miami, Florida.

For Use When Taking Pills Is Difficult

In December, an FDA panel of independent experts voted to recommend that the patch's label encourage its use as an alternative treatment for children ages 6 to 12 with ADHD, meaning doctors should prescribe it only if taking pills is too difficult for a child. ADHD is a condition in some children that makes concentration and learning difficult.

Unlike pill forms of the drug, the patch can be removed should it cause side effects.

Noven Pharmaceuticals submitted a 12-hour version of the patch to the FDA in 2003. The agency rejected it and recommended that Noven test a nine-hour version. That version was approved for use Thursday.

Shire Pharmaceuticals Group PLC, based in Britain, co-developed the patch with Noven Pharmaceuticals.

Risk of Stroke, Hallucinations

Approval of the patch comes as use of methylphenidate and other ADHD drugs increases in the United States. Nearly 3.3 million Americans age 19 and younger used an ADHD drug last year, according to Medco Health Solutions Inc., a prescription drug benefit program manager.

The FDA continues to grapple with whether to require more severe warnings on the labels of the drugs.

A panel of outside experts recently recommended to the FDA that the drugs bear labels that caution users in plain language about possible dangers, including stroke and hallucinations. Earlier, another FDA panel recommended that the medicines include so-called "black-box" warnings, the strongest warnings a prescription drug can bear.




 
Sponsored Text Links
SkinStore.com: StriVectin-SD
Hydroderm: Body Shape - Proven to be safe and effective - Free Trial!
InsureMe.com: Click here to get a free health insurance quote.
Hydroderm: Lose wrinkles with Hydroderm
SkinStore.com: Strivectin SD 6oz Best Price Offer